Search

Your search keyword '"Yamada, Y."' showing total 119 results

Search Constraints

Start Over You searched for: Author "Yamada, Y." Remove constraint Author: "Yamada, Y." Journal annals of oncology Remove constraint Journal: annals of oncology
119 results on '"Yamada, Y."'

Search Results

1. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial

3. Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group

5. 723P Medical expenditures and treatment efficacy of patients who had initial hepatocellular carcinoma and underwent surgery or radiofrequency ablation: Accompanying research of the SURF trial

10. 1662P Comprehensive analysis of the metabolic enzymes in patients with small cell lung cancer using a large-scale targeted proteomics assay

26. A phase 1 study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies

27. Change in the molecular profile of tumor tissues during treatment with trastuzumab, as analyzed by next-generation sequencing and immunohistochemistry: A multicenter prospective biomarker study on HER2-positive gastric cancer

32. LBA-08 Results of a phase 1b study of the selective BRAF V600 inhibitor encorafenib in combination with cetuximab alone or cetuximab + alpelisib for treatment of patients with advanced BRAF-mutant metastatic colorectal cancer

33. P-136 De novo malignancy after living donor liver transplantation

36. Amrubicin Monotherapy in Patients with Platinum-Refractory Metastatic Neuroendocrine Carcinoma and Mixed Adenoneuroendocrine Carcinoma of the Gastrointestinal Tract

38. Impacts of Progression Type on Overall Survival in Advanced Gastric Cancer: Randomized Piii Study of S-1 + Oxaliplatin Vs. S-1 + Cisplatin

39. Phase || Study of Pemetrexed + Carboplatin + Bevacizumab As First-Line Therapy for Nonsquamous Non-Small Cell Lung Cancer with Egfr Mutation, Result of Induction Therapy: Central Japan Lung Study Group (Cjlsg) 0910 Trial

50. Phase I and Pharmacokinetics/Pharmacodynamics (PK/PD) Study of RO5126766, a First-in-Class Dual Raf/Mek Inhibitor, in Japanese Patients with Advanced Solid Tumors

Catalog

Books, media, physical & digital resources